

## Wegovy® (semaglutide) - Expanded indication

- On December 23, 2022, <u>Novo Nordisk announced</u> the <u>FDA approval</u> of <u>Wegovy (semaglutide)</u>, for chronic weight management in pediatric patients aged 12 years and older with an initial body mass index (BMI) at the 95th percentile or greater for age and sex (obesity).
  - Wegovy was previously approved in adult patients only as outlined below.
- Wegovy is also approved for chronic weight management in adults with an initial BMI of 30 kg/m<sup>2</sup> or greater (obesity) or a BMI 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).
- The approval of Wegovy for the expanded indication was based on a 68-week, double-blind, randomized, parallel group, placebo-controlled study of 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to ≥ 95th percentile standardized for age and sex. Patients received Wegovy or placebo once weekly. The primary endpoint was percent change in BMI from baseline to week 68.
  - At week 68, the least squares mean change in BMI was -16.1% for Wegovy-treated patients vs. 0.6% for placebo-treated patients (treatment difference -16.7%; 95% CI: -20.3, -13.2; p < 0.0001).</li>
- Wegovy carries a boxed warning for risk of thyroid C-cell tumors.
- The recommended initial dose of Wegovy for the treatment of adults and pediatric patients 12
  years of age and older is a dosage of 0.25 mg injected subcutaneously (SC) once weekly. Then
  follow the dose escalation schedule outlined in the drug label to minimize gastrointestinal adverse
  reactions.
  - In pediatric patients, the recommended maintenance dosage of Wegovy is 2.4 mg injected SC once weekly. If patients do not tolerate the maintenance 2.4 mg once-weekly dosage, the maintenance dosage may be reduced to 1.7 mg once weekly. Wegovy should be discontinued if the patient cannot tolerate the 1.7 mg dose.
  - Refer to the Wegovy drug label for further information about adult and pediatric dosing for all its indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.